NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), operates one of Canada’s largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain medical services, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 10, 2026 and the grant of restricted share units (“RSUs”) and common shares. All figures are in Canadian dollars, unless otherwise noted.

The results of the director elections were as follows:

Name	Votes in Favour	% Votes in Favour	Votes Withheld	% Votes Withheld
Jolyon Burton	14,716,268	99.99%	1,000	0.01%
Daniel Chicoine	14,716,268	99.99%	1,000	0.01%
Sasha Cucuz	14,697,208	99.86%	20,060	0.14%
Dan Legault	14,716,268	99.99%	1,000	0.01%
Joseph Walewicz	14,711,268	99.96%	6,000	0.04%

The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, (ii) to approve the Company’s amended and restated stock option plan in the form attached as Schedule “A” to the management information circular dated April 21, 2026 prepared in connection with the Meeting (the “Circular”), (iii) to approve the Company’s second amended and restated restricted share unit plan in the form attached as Schedule “B” to the Circular (the “RSU Plan”), and (iv) to approve the issuance of 893,616 common shares in the capital of the Company in settlement of $420,000 indebtedness owing to Joseph Walewicz, the Company’s former Chief Executive Officer, and Jeff Zygouras, the Company’s Chief Financial Officer (the “Shares for Debt Transaction”), as more particularly described in the Circular.

Amendments to the RSU Plan

At the Meeting, approximately 86.80% of the votes cast by shareholders were voted in favour of adopting the RSU Plan. The principal amendments to the RSU Plan include: (i) restricting settlement of all restricted share units (“RSUs”) granted under the plan to Common Shares issued from treasury, thereby eliminating all alternative settlement methods, including cash settlement and settlement through the delivery of Common Shares acquired on the open market; (ii) introducing a mechanism permitting eligible participants (other than U.S. taxpayers) to elect a settlement date for vested RSUs within a specified period following vesting, up to a maximum of seven years from the applicable grant date; and (iii) implementing certain additional conforming and administrative amendments necessary or advisable to give effect to the foregoing changes. The material terms of the RSU Plan otherwise remain substantially consistent with the Company’s prior restricted share unit plan. The maximum number of common shares authorized for issuance and reserved under the RSU Plan is 5,000,000 common shares.

Issuance of Restricted Share Units

On June 11, 2026, NeuPath granted an aggregate of 200,000 RSUs to non-executive directors of the Company. The RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted will fully vest on June 11, 2027. The terms of the RSUs granted are in accordance with the RSU Plan.

Issuance of Common Shares of Proposed Shares for Debt Settlement

At the Meeting, approximately 99.81% of the votes cast by disinterested shareholders were voted in favour of approving the Shares for Debt Transaction. This excluded votes attaching to common shares beneficially owned, or over control or direction is exercised, held by Mr. Walewicz, Mr. Zygouras and any of their respective associates and affiliates. On June 11, 2026, pursuant to the Shares for Debt Transaction, the Company issued an aggregate of 893,616 common shares in the capital of the Company at a deemed price of $0.47 per common share, being the closing price of the common shares on the TSX Venture Exchange on March 31, 2026.

About NeuPath

NeuPath operates one of Canada’s largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain medical services. NeuPath provides improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. Working within Canada’s publicly funded healthcare system, NeuPath delivers insured medical services to help extend the appropriate care from hospitals into the community, which are complemented by select non-insured procedures to provide a comprehensive and coordinated treatment for patients. For additional information, please visit www.neupath.com.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.